VIR
Vir Biotechnology, Inc.
Biotechnology · Healthcare · United States
11.30
close · 2026-10-30
value
54
cheaper than peers54
quality
96
stronger fundamentals96
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 33.9% | 100 |
| cash flow yield, 3 years ago | 83.4% | 99 |
| price to book | 1.95× | 70 |
| price to sales | 6.31× | 64 |
| earnings yield, latest year | -28.0% | 35 |
| earnings yield, 1 year ago | -33.9% | 35 |
| cash flow yield, latest year | -20.7% | 34 |
| earnings yield, 2 years ago | -40.6% | 33 |
| cash flow yield, 1 year ago | -23.7% | 28 |
| cash flow yield, 2 years ago | -41.9% | 23 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 19582.5% | 99 |
| operating margin | 30.7% | 90 |
| return on equity | -26.1% | 68 |
| debt to equity | 9.5% | 62 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$39.1M |
| employees | 367 |
| first trade | 2019-10-11 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.16 | -3.83 | -4.59 | 3.83 |
| free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.60B |
| net income | -$438.0M | -$522.0M | -$615.1M | $515.8M |
| revenue | $66.5M | $63.7M | $39.5M | $1.58B |
| unusual items | $1.9M | -$40.5M | -$35.4M | -$111.1M |